End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

PET Clinics ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. 307-315 ◽  
Author(s):  
Lale Kostakoglu ◽  
Grzegorz S. Nowakowski
Keyword(s):  
Computed Tomography ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
End Of Treatment ◽  
Large B Cell

End-of-treatment 18F-FDG PET/CT in diffuse large B cell lymphoma patients: ΔSUV outperforms Deauville score

2021 ◽  
pp. 1-9
Author(s):  
François Allioux ◽  
Damaj Gandhi ◽  
Jean-Pierre Vilque ◽  
Cathy Nganoa ◽  
Anne-Claire Gac ◽  
...  
Keyword(s):  
B Cell ◽  
Fdg Pet ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
End Of Treatment ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Large B Cell

scholarly journals Single Centre Retrospective Analysis: Transformation of Waldenström's Macroglobulinemia to Diffuse Large B-Cell Lymphoma

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 11-11
Author(s):  
Bert Heyrman ◽  
Nikki Granacher ◽  
Ka Lung Wu
Keyword(s):  
B Cell ◽  
Retrospective Analysis ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Single Centre ◽  
The Past ◽  
Large B Cell Lymphoma ◽  
End Of Treatment ◽  
Large B Cell

Introduction: The incidence and outcome of Waldenström's macroglobulinemia (WM) patients with transformation to diffuse large B-cell lymphoma (DLBCL) are unclear. We performed a retrospective analysis to determine the incidence, clinicopathological characteristics and treatment outcome of WM patient with histologic transformation to DLBCL in our centre. Methods: Single centre chart review of WM patients in the past 10 years. Patients with histologic diagnosis of DLBCL after the diagnosis WM were included in our analysis. Results: Three of the 79 WM patients had histological transformation to DLBCL, two male and one female. Mean age at DLBCL development was 76,6 years. The mean time to transformation since diagnosis of WM was 8,3 years (14, 8 and 3 years). All three patients received at least one prior line of treatment in relation to WM (2, 1 and 3 prior lines). Different regimens used were cyclophosphamide/dexamethasone, rituximab/bendamustin, chlorambucil monotherapy, fludarabine monotherapy, R-CVP and ibrutinib monotherapy. The patients were in clinical CR from WM at the time of transformation, two patients were still on treatment. All three patients presented with advanced disease (stage IIIB, IVB, and IVA) non-GCB subtype DLBCL with at least 2 extra nodal sites. R-IPI scores were 4,5 and 4. Two patients were treated with R-miniCHOP, one patient received R-CHOP. The first patient achieved a CR at the end of treatment and is now 1,5 years in follow-up. The second patient died from pneumonia one year after achieving a CR. The third patient is in follow op since 3 months after reaching a CR at the end of treatment. Conclusion: Over the past decade transformation of WM to DLBCL was 3.7% in our centre. This is in accordance with previous data suggesting an 2.4% risk of transformation over 10 years.Time to transformation varies and no association with prior WM therapy and response to treatment can be found.All patients presented with more aggressive DLBCL in an advanced stage.All three patients achieved a CR following treatment for DLBCL, one patient died from pneumonia, two others are now in follow-up 1,5 years and 3 months respectively. Disclosures Heyrman: Celgene:Research Funding.

First-Line Treatment with R-Chop/21 for Patients with Disseminated Diffuse Large B-Cell Lymphoma (DLCL). Results of a Prospective Series of 128 Patients.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4573-4573
Author(s):  
E. Gonzalez-Barca ◽  
E. Domingo-Domenech ◽  
J. M. Ribera ◽  
J. Briones ◽  
A. Salar ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Survival Curves ◽  
Large B Cell Lymphoma ◽  
End Of Treatment ◽  
Historical Series ◽  
Gallium 67 ◽  
Large B Cell

Abstract Purpose: to analize the response rate and survival of a series of patients with disseminated large B-cell lymphoma treated with R-CHOP/21 x 8 cycles and to evaluate the prognostic factors and the prognostic value of gallium-67 imaging. Patients and Methods: 128 patients with DLCL have been prospectively treated with R-CHOP/21 from March 2002 to March 2004, ages between 18 and 85 years. Survival curves were expressed as Kaplan-Meier plots. Prognostic factors were evaluated by the Chi-square test. Survival curves were compared by the Log-rank test. Results: the median age was 65 years (limits: 27–83), 31% older than 70 years. 59 (54%) patients were males. Gallium imaging was positive at diagnosis in 91%. Clinical presentation of DLCL was: bulky disease: 40%, extra-nodal disease: 66% (³ 2 sites: 33%), B symptoms: 41%, ECOG ³ 2: 53%, LDH>N: 67%, IPI ³ 3: 60%. Chemotherapy cycles received were: <6: 20%; 6: 34%; 8: 46%. The intention-to-treat response was: CR 72%, PR 11%, failures 11%, not evaluable: 6%. Survival, with a median follow-up of 13 months, was: OS: 74%, and EFS: 70%. There are no differences between patients who have been treated with 6 or 8 cycles. EFS of patients with normal gallium imaging at the end of treatment was 90% (p=0.03). EFS was not different between patients older or younger than 70 years. EFS of patients with age adjusted IPI 0 was 100%, IPI 1:70%; IPI 3: 82% and IPI 4: 48%. Three (5%) patients relapsed. Prognostic factors for OS and EFS were: LDH > Normal (p=0.01 y p=0.005 respectively) and ECOG ³ 2 (p=0.0008 y p=0.02). Conclusion: Rituximab associated with CHOP improves the results of historical series treated with CHOP for patients of all ages, but in patients with age-adjusted IPI=3 results have to be improved with other therapeutic strategies. Normalization of gallium-67 imaging at the end of treatment is predictive of a significantly better EFS. Age is not a prognostic factor in patients who receive the same treatment. For patients with disseminated disease, LDH and ECOG are the only significant prognostic factors.

scholarly journals An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review

2017 ◽  
Vol 5 ◽  
pp. 2050313X1770919 ◽  
Author(s):  
Sih-Han Liao ◽  
Yin-Kai Chen ◽  
Shan-Chi Yu ◽  
Ming-Shiang Wu ◽  
Hsiu-Po Wang ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Hepatic Tumors ◽  
Primary Hepatic Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Objectives: Primary hepatic lymphoma is an uncommon cause of hepatic space-occupying lesions. Methods: We describe the case of a 73-year-old man with primary hepatic lymphoma, who presented with a low-grade fever and lower limb weakness which had progressed in the past 2 months. Results: Abdominal ultrasound and computed tomography showed multiple small hepatic tumors. Echo-guided biopsy of the hepatic tumor demonstrated primary hepatic diffuse large B cell lymphoma. Moreover, bone marrow was uninvolved, but the bone marrow smear disclosed hemophagocytosis, which is uncommon in diffuse large B cell lymphoma. Chemotherapy with bendamustine and rituximab treatment was initiated with a dramatic response: hepatic tumors markedly shrank in size shown by follow-up computed tomography and the patient returned to his normal life. Nevertheless, the response was sustained for only 8 months. Finally, the disease resisted further chemotherapy and this patient died of a severe Klebsiella pneumoniae infection. Conclusion: Chemotherapy with bendamustine and rituximab has shown a dramatic, but not durable, response in the present case with old age and multiple comorbidities.

Sign in / Sign up

Export Citation Format

Share Document